Mark B. Rourke sold $2.6M of SNDR
Executive Chair at Schneider National, Inc.. 72,994 shares at an average of $35.73, traded Aug 3, 2026, filed Aug 5, 2026.
Score components
- +20RoleChair
- +25Trade size$2.6M at market
- +10Share of holdings soldSold 30% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001699618-26-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | MOption exercise Class B Common Stock | +20,312 | $24.81 | $504k | 241,834 | Aug 5, 2026 |
| Aug 3, 2026 | SOpen-market sale Class B Common Stock | -20,312 | $35.18 | $715k | 221,522 | Aug 5, 2026 |
| Aug 4, 2026 | MOption exercise Class B Common Stock | +24,000 | $20.96 | $503k | 245,522 | Aug 5, 2026 |
| Aug 4, 2026 | SOpen-market sale Class B Common Stock | -24,000 | $36.12 | $867k | 221,522 | Aug 5, 2026 |
| Aug 4, 2026 | MOption exercise Class B Common Stock | +13,208 | $24.81 | $328k | 234,730 | Aug 5, 2026 |
| Aug 4, 2026 | MOption exercise Class B Common Stock | +15,474 | $20.96 | $324k | 250,204 | Aug 5, 2026 |
| Aug 4, 2026 | SOpen-market sale Class B Common Stock | -15,474 | $35.98 | $557k | 234,730 | Aug 5, 2026 |
| Aug 4, 2026 | SOpen-market sale Class B Common Stock | -13,208 | $35.58 | $470k | 221,522 | Aug 5, 2026 |
| Aug 3, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative | -20,312 | $0.00 | $0 | 13,208 | Aug 5, 2026 |
| Aug 4, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative | -13,208 | $0.00 | $0 | 0 | Aug 5, 2026 |
| Aug 4, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative | -24,000 | $0.00 | $0 | 15,474 | Aug 5, 2026 |
| Aug 4, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative | -15,474 | $0.00 | $0 | 0 | Aug 5, 2026 |
Related signals
Other insiders at Schneider National, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | Schneider National, Inc. | Thomas G Jackson EVP - General Counsel | $753k 20,271 shares | -21% | |
| 27Weak | Schneider National, Inc. | Shaleen Devgun EVP-Chief Innovation, Tech | $322k 8,352 shares | -18% | |
| 31Weak | Schneider National, Inc. | Magnin Shelly A Dumas VP and Corporate Controller | $75k 2,425 shares | -9% | |
| 30Weak | Schneider National, Inc. | Angela M Fish EVP Human Resources | $427k 14,119 shares | -22% | |
| 33Weak | SNDRsell Schneider National, Inc. | Darrell George Campbell EVP - CFO | $173k 6,000 shares | -8% | |
| 33Weak | SNDRsell Schneider National, Inc. | Thomas G Jackson EVP - General Counsel | $892k 36,596 shares | -33% | |
| 29Weak | SNDRsell Schneider National, Inc. | Shaleen Devgun Chief Innovation, Tech Officer | $290k 10,000 shares | -10% | |
| 27Weak | Schneider National, Inc. | Robert M Reich JR EVP - CAO | $198k 6,250 shares | -4% | |
| 39Weak | Schneider National, Inc. | Thomas G Jackson EVP - General Counsel | $603k 18,248 shares | -22% | |
| 50Moderate | Schneider National, Inc. | Mark B. Rourke EVP & COO | $1.1M 32,057 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.